Immunology News and Research

Latest Immunology News and Research

Phase 2 study of AR101 meets primary endpoint in patients with peanut allergy

Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that a Phase 2 study (ARC001) evaluating the company's lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively.

10 Jun 2015

New research shows how human immune system could be manipulated to better fight disease

New research from Australian and Singaporean scientists has revealed how immune cell 'spies' are created, providing clues on how the immune system could be manipulated to better fight disease.

9 Jun 2015

Enhancing body's gut defense system can reverse bloodstream infections

An upset in the body's natural balance of gut bacteria that may lead to life-threatening bloodstream infections can be reversed by enhancing a specific immune defense response, UT Southwestern Medical Center researchers have found.

9 Jun 2015

Cell fusion triggers multiple genetic changes that convert normal cells to cancer cells

Although there is no one established universal cause of cancer, genetic changes are central to its development. The accumulation of spontaneous genetic changes, or mutations, that occur when cells divide can be hastened by exposure to carcinogens such as cigarette smoke (lung cancer) and infectious agents such as the papillomavirus (cervical cancer).

9 Jun 2015

Nuvo obtains Health Canada approval to conduct WF10 Phase 2 trial for treatment of allergic rhinitis

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced it has received Health Canada approval to conduct a new Phase 2 clinical trial (the 2015 WF10 Trial) to assess WF10 for the treatment of allergic rhinitis.

8 Jun 2015

BioLineRx's BL-9020 antibody holds promise in treating Type 1 diabetes

Type 1 diabetes, which usually appears in children and adolescents, affects over 30 million people worldwide. Resulting from an auto-immune reaction that destroys the pancreatic beta cells that produce insulin, the disease leads to pathologically high levels of sugar in the blood and urine, resulting in high rates of morbidity and mortality. The current treatment for Type 1 diabetes is lifetime administration of insulin by injection.

8 Jun 2015

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD.

7 Jun 2015

New Tel Aviv University research introduces promising new tool to combat antibiotic-resistant pathogens

At its annual assembly in Geneva last week, the World Health Organization approved a radical and far-reaching plan to slow the rapid, extensive spread of antibiotic resistance around the world. The plan hopes to curb the rise caused by an unchecked use of antibiotics and lack of new antibiotics on the market.

5 Jun 2015

Seattle Children's opens enrollment for first clinical trial of Tumor Paint BLZ-100 for children with brain tumors

Seattle Children's today announced the opening of patient enrollment for the first clinical research trial of the drug Tumor Paint BLZ-100, which is designed to improve surgical outcomes in children with brain tumors – the most common solid tumor cancer in kids.

5 Jun 2015

Penn Medicine researchers explore primary player involved in T cell exhaustion

Sometimes even cells get tired. When the T cells of your immune system are forced to deal over time with cancer or a chronic infection such as HIV or hepatitis C, they can develop 'T cell exhaustion,' becoming less effective and losing their ability to attack and destroy the invaders of the body.

4 Jun 2015

Better treatment, prevention strategies still needed for opportunistic infections related to AIDS

Although treatment advances have dramatically reduced deaths from opportunistic infections related to AIDS, a new study drawing on 30 years of data from more than 20,000 patients in San Francisco suggests there is still ample room to improve. About a third--35 percent--of AIDS patients diagnosed with their first opportunistic infection from 1997 to 2012 in that city died within five years, according to the study, published in the Journal of Infectious Diseases.

4 Jun 2015

Roche announces FDA 510(k) clearance for cobas HSV 1 and 2 Test

Roche announced today that the US Food and Drug Administration has provided 510(k) clearance for the cobas HSV 1 and 2 Test for the direct detection and differentiation of HSV-1 and HSV-2 DNA in anogenital specimens from symptomatic patients. With dual target detection and automation, the cobas HSV 1 and 2 Test provides laboratories with the capability to report up to 94 results in significantly less time than traditional methods and provides a simplified workflow for sample handling in the laboratory.

4 Jun 2015

Researchers discover new pathway that may be vital for understanding allergic asthma

Researchers at the Centenary Institute have discovered a new pathway that may be vital for our understanding allergic asthma, the most common form of asthma and the prevalent form of childhood-onset asthma affecting 2 million Australians.

3 Jun 2015

New finding may lead to development of immunity-based therapies for tuberculosis

A study by researchers at UT Southwestern Medical Center has identified how an enzyme involved in protecting the body from pathogens senses Mycobacterium tuberculosis (TB), a bacterial pathogen that infects millions of people worldwide and causes about 1.5 million deaths annually.

2 Jun 2015

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Janssen Research & Development, LLC announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival with trabectedin (YONDELIS®) compared to dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with an anthracycline and at least one additional chemotherapy regimen.

2 Jun 2015

Groundbreaking, combination vaccine may help beat Streptococcus A infections

Griffith University's Institute for Glycomics has developed a groundbreaking, combination vaccine that may finally beat Streptococcus A infections.

2 Jun 2015

Group Health Research Institute conducts first randomized trial to tackle vaccine hesitancy

Group Health Research Institute conducted the first randomized trial to test an intervention aimed at improving hesitancy about early childhood vaccines by working directly with doctors. Vax Northwest, a Washington state public-private partnership, developed the intervention.

2 Jun 2015

Mount Sinai Health System researchers present updates on cancer vaccine clinical trials at ASCO 2015

Mount Sinai Health System faculty will be presenting research updates on a lymphoma vaccine clinical trial, the best dosing for a drug against metastatic cancer, and new treatment strategies in relapsed multiple myeloma at the American Society of Clinical Oncology annual meeting, May 29 - June 2, 2015, in Chicago.

2 Jun 2015

University of Southampton and BioInvent enter collaboration to develop new cancer immunotherapies

Leading antibody researchers at the University of Southampton, under the direction of Professor Mark Cragg, Professor of Experimental Cancer Research and Director of the Cancer Pathway Integrated Postgraduate Programme, today announce a three-year research collaboration with BioInvent International.

1 Jun 2015

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.

1 Jun 2015

Immunology News and Research

Latest Immunology News and Research

Phase 2 study of AR101 meets primary endpoint in patients with peanut allergy

New research shows how human immune system could be manipulated to better fight disease

Enhancing body's gut defense system can reverse bloodstream infections

Cell fusion triggers multiple genetic changes that convert normal cells to cancer cells

Nuvo obtains Health Canada approval to conduct WF10 Phase 2 trial for treatment of allergic rhinitis

BioLineRx's BL-9020 antibody holds promise in treating Type 1 diabetes

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

New Tel Aviv University research introduces promising new tool to combat antibiotic-resistant pathogens

Seattle Children's opens enrollment for first clinical trial of Tumor Paint BLZ-100 for children with brain tumors

Penn Medicine researchers explore primary player involved in T cell exhaustion

Better treatment, prevention strategies still needed for opportunistic infections related to AIDS

Roche announces FDA 510(k) clearance for cobas HSV 1 and 2 Test

Researchers discover new pathway that may be vital for understanding allergic asthma

New finding may lead to development of immunity-based therapies for tuberculosis

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Groundbreaking, combination vaccine may help beat Streptococcus A infections

Group Health Research Institute conducts first randomized trial to tackle vaccine hesitancy

Mount Sinai Health System researchers present updates on cancer vaccine clinical trials at ASCO 2015

University of Southampton and BioInvent enter collaboration to develop new cancer immunotherapies

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Immunology eBook

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Exploring the G:Box and for high-quality imaging